SCHEMBL1734697

SCHEMBL1734697

CCCS(=O)(=O)N1CC1C(=O)OC

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.41
ANPEP P15144 2/20 0.41
MAPT P10636 4/20 0.40
ALDH1A1 P00352 3/20 0.39
KMT2A Q03164 2/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 2/20 0.38
CYP1A2 P05177 2/20 0.37
ELOVL6 Q9H5J4 1/20 0.37
FKBP1A P62942 2/20 0.36
CYP3A4 P08684 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.35
MMP3 P08254 1/20 0.35
MMP8 P22894 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089950 0.76 MAPK1 (0.50) MAPTALDH1A1KMT2AMAPK1SMN1; SMN2
Hydrochloric Acid SCHEMBL9232192 0.74 ELOVL6 (0.38) MMP2ANPEPMAPTALDH1A1LMNA
SCHEMBL23464669 0.71 MMP2 (0.42) MMP2ANPEPALDH1A1KMT2A
SCHEMBL1734696 0.71 MMP2 (0.42) MMP2ANPEPALDH1A1KMT2AELOVL6
SCHEMBL23630446 0.69 ALDH1A1 (0.54) MMP2ANPEPALDH1A1KMT2ALMNA
SCHEMBL28481811 0.69 ALDH1A1 (0.38) MAPTALDH1A1KMT2AMAPK1SMN1; SMN2
SCHEMBL23630430 0.68 MMP3 (0.64) MMP2MMP3MMP8
SCHEMBL23630336 0.68 MMP1 (0.53) MMP2ANPEPALDH1A1KMT2ASMN1; SMN2
SCHEMBL2890630 0.68 ELOVL6 (0.64) SMN1; SMN2ELOVL6HTT
SCHEMBL29306521 0.67 CYP3A4 (0.45) MMP2ANPEPMAPTMAPK1FKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 EP disclosed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 WO disclosed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 US disclosed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES NR1H2, NR1H3, NR1I2 MMP2 4754/4885ANPEP 4486/4885MAPT 4023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.